Edwards Lifesciences (EW) Misses Q4 EPS by 3c, Offers Q1 and FY Guidance

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.50, $0.03 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.19 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2021 EPS of $0.43-$0.53, versus the consensus of $0.50. Edwards Lifesciences sees Q1 2021 revenue of $1.1-1.2 billion, versus the consensus of $1.21 billion.

Edwards Lifesciences sees FY2021 EPS of $2.00-$2.10, versus the consensus of $2.15. Edwards Lifesciences sees FY2021 revenue of $4.9-5.3 billion, versus the consensus of $5.09 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c